文献速递前列腺癌

MRI-超声融合与器官追踪引导下经会阴靶向微波消融治疗局限性前列腺癌的初步研究

Transperineal Targeted Microwave Ablation (TMA) of localized prostate cancer guided by MRI-Ultrasound fusion and organ-based tracking: a pilot study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-07-14

单中心前瞻性2期试验纳入低至中危局限性前列腺癌男性,行MRI-超声融合与器官追踪引导的经会阴靶向微波消融(TMA)。前15例共治疗23个区域,6个月活检示91.3%(21/23)消融区无癌,每例分析33.3%(5/15)有阳性活检;作者认为TMA有效、安全且易于应用。

要点

  • 前15例共治疗23个区域,6个月活检91.3%(21/23)消融区无癌。
  • 每例分析中33.3%(5/15)在6个月时有野内或野外阳性活检。
  • 5例阳性中4例适合主动监测,1例(6.7%)野外ISUP 2级接受放疗。

核心结论

  • 在这项首次初步研究中,MRI-超声融合与器官追踪引导的经会阴TMA在局限性前列腺癌男性中显示有效、安全且易于应用。

研究设计与样本

  • 单中心前瞻性2期试验,招募低至中危局限性前列腺癌男性接受经会阴TMA,采用MRI-超声融合引导与器官追踪,按方案行6个月MRI和活检。

主要发现

  • 前15例共治疗23个区域,中位年龄70岁,TMA消融次数中位5次(范围2-8),总消融时间中位22分钟(IQR 14-28),手术时间中位75分钟(IQR 65-85)。
  • PSA中位值从7.7降至2.4 ng/mL。
  • 主要结局:91.3%(21/23)消融区在6个月活检中无癌;每例分析中33.3%(5/15)在6个月时有野内或野外阳性活检。
  • 5例阳性中4例适合主动监测,1例(6.7%)野外ISUP 2级癌接受放疗。
  • 6个月时泌尿症状、尿流率、勃起功能与生活质量评分无显著差异;5例勃起正常者中1例主诉TMA后勃起功能明显恶化。

临床怎么用

  • 作者认为,MRI-超声融合与器官追踪引导的经会阴TMA在局限性前列腺癌男性中有效、安全且易于应用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To investigate the efficacy of transperineal targeted microwave ablation (TMA) in treating localized prostate cancer (PCa). METHODS: This is a single-centre prospective phase 2 trial recruiting men with low to intermediate-risk localized PCa to undergo transperineal TMA. TMA was performed with MRI-Ultrasound fusion guidance and organ-based tracking. A per-protocol 6-month MRI and biopsy were performed for all patients. The primary outcome was any cancer detected on biopsy of each ablated area. Secondary outcomes included per-patient analysis of positive biopsy, complications, urinary symptom score, erectile function and quality of life (QOL) scores. RESULTS: In the first 15 men, 23 areas were being treated. The median age was 70 years, number of TMA ablations were 5 (range 2-8), and the total ablation time and operating time was 22 (IQR 14-28) and 75 (IQR 65-85) minutes, respectively. PSA level dropped from a median of 7.7 to 2.4 ng/mL. For the primary outcome, 91.3% (21/23) ablated area had no cancer in 6-month biopsy. In per-patient analysis, 33.3% (5/15) had in or out-of-field positive biopsy at 6 months. Among these five cases, four of them were amenable to active surveillance and 1 (6.7%) case with out-of-field ISUP grade group 2 cancer received radiotherapy. The urinary symptoms, uroflowmetry, erectile function, and QOL scores had no significant difference at 6 months. One patient (out of five patients with normal erection) in the cohort complained of significant worsening of erectile function after TMA. Grade 1 complications including hematuria (33.3%), dysuria (6.7%), and perineal discomfort (13.4%) were observed. CONCLUSIONS: In this first pilot study, transperineal TMA guided by MRI-Ultrasound fusion guidance and organ-based tracking was shown to be effective, safe, and easily applicable in men with localized PCa.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Chiu PK, Chan CH, Yee CH, et al. Transperineal Targeted Microwave Ablation (TMA) of localized prostate cancer guided by MRI-Ultrasound fusion and organ-based tracking: a pilot study. Prostate Cancer Prostatic Dis. 2022. PMID: 35835844. doi:10.1038/s41391-022-00577-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。